Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease JACC Review Topic of the Week

被引：85

作者：

Mantovani, Alessandro ^{[1
,2
]}

Byrne, Christopher D. ^{[3
]}

Benfari, Giovanni ^{[2
,4
]}

Bonapace, Stefano ^{[5
]}

Simon, Tracey G. ^{[6
,7
,8
]}

Targher, Giovanni ^{[1
,2
]}

机构：

[1] Univ Verona, Sect Endocrinol Diabet & Metab, Dept Med, Piazzale Stefani 1, I-37126 Verona, Italy

[2] Azienda Osped Univ Integrata Verona, Verona, Italy

[3] Univ Hosp Southampton, Southampton Natl Inst Hlth Res Biomed Res Ctr, Southampton, Hants, England

[4] Univ Verona, Dept Med, Sect Cardiol, Verona, Italy

[5] IRCSS Sacro Cuore Don Calabria, Sect Cardiol, Negrar, VR, Italy

[6] Massachusetts Gen Hosp, Dept Med, Liver Ctr, Div Gastroenterol, Boston, MA 02114 USA

[7] Harvard Med Sch, Boston, MA 02115 USA

[8] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit CTEU, Boston, MA 02114 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 02期

基金：

美国国家卫生研究院;

关键词：

heart failure; NAFLD; NASH; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; SGLT2-inhibitors; GAMMA-GLUTAMYL-TRANSFERASE; RENIN-ANGIOTENSIN SYSTEM; GLP-1 RECEPTOR AGONISTS; TRIMETHYLAMINE-N-OXIDE; NECROSIS-FACTOR-ALPHA; ATRIAL-FIBRILLATION; BARIATRIC SURGERY; KIDNEY OUTCOMES; ASSOCIATION; DYSFUNCTION;

D O I：

10.1016/j.jacc.2021.11.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems. Emerging evidence supports a strong and independent association between NAFLD and the risk of new-onset HF, and there are multiple potential pathophysiological mechanisms by which NAFLD may increase risk of new-onset HF. The magnitude of this risk parallels the underlying severity of NAFLD, especially the level of liver fibrosis. Patients with NAFLD develop accelerated coronary atherosclerosis, myocardial alterations (mainly cardiac remodeling and hypertrophy), and certain arrhythmias (mainly atrial fibrillation), which may precede and promote the development of new-onset HF. This brief narrative review aims to provide an overview of the association between NAFLD and increased risk of new-onset HF, discuss the underlying mechanisms that link these 2 diseases, and summarize targeted pharmacological treatments for NAFLD that might also reduce the risk of HF. (C) 2022 by the American College of Cardiology Foundation.

引用

页码：180 / 191

页数：12

共 81 条

[1] The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the 13C-ketoisocaproate breath test [J].

Afolabi, Paul R. ;

Scorletti, Eleonora ;

Smith, Debbie E. ;

Almehmadi, Amal A. ;

Calder, Philip C. ;

Byrne, Christopher D. .

JOURNAL OF BREATH RESEARCH, 2018, 12 (04)

[2] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[3] Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease [J].

Anstee, Quentin M. ;

Mantovani, Alessandro ;

Tilg, Herbert ;

Targher, Giovanni .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2018, 15 (07) :425-439

[4] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[5] Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: A concise review [J].

Aung, Lynn Htet Htet ;

Jumbo, Juan Carlos Cueva ;

Wang, Yin ;

Li, Peifeng .

MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 25 :416-443

[6]

McDonagh Theresa A, 2022, Rev Esp Cardiol (Engl Ed), V75, P523, DOI [10.1002/ejhf.2333, 10.1093/eurheartj/ehab368, 10.1016/j.rec.2022.05.005]

[7] Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis [J].

Borges-Canha, Marta ;

Neves, Joao Sergio ;

Libanio, Diogo ;

Von-Hafe, Madalena ;

Vale, Catarina ;

Araujo-Martins, Miguel ;

Leite, Ana Rita ;

Pimentel-Nunes, Pedro ;

Carvalho, Davide ;

Leite-Moreira, Adelino .

ENDOCRINE, 2019, 66 (03) :467-476

[8] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications [J].

Brown, Emily ;

Heerspink, Hiddo J. L. ;

Cuthbertson, Daniel J. ;

Wilding, John P. H. .

LANCET, 2021, 398 (10296) :262-276

[9] Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications [J].

Byrne, Christopher D. ;

Targher, Giovanni .

DIABETES OBESITY & METABOLISM, 2022, 24 :28-43

[10] Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation [J].

Cai, Xiaoyan ;

Zheng, Sulin ;

Liu, Ying ;

Zhang, Yan ;

Lu, Jianhua ;

Huang, Yuli .

LIVER INTERNATIONAL, 2020, 40 (07) :1594-1600

← 1 2 3 4 5 6 7 8 9 →